The UK and US have announced a important trade agreement that will preserve zero duties on British medicine shipments being sold in the US market.
The Terms of the Deal
As part of the deal, the UK has agreed to increase spending on drugs through the public health system. This move secures that import taxes on these crucial goods will be held at zero for a period of three years.
This development comes after previous statements to significantly raise tariffs on branded pharmaceutical products, with increases floated up to double the cost.
"This deal between the Britain strengthens the global environment for new treatments and establishes much-needed fairness to American-British medicine commerce," a statement declared.
Economic Impact
Drugs are one of the the United Kingdom's largest goods shipped to the US, which is by far the biggest destination for major companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months to the end of September, the UK shipped medicines valued at billions to the US. This amount represented 17.4% of British export trade in that period.
"This agreement safeguards jobs, stimulates capital expenditure and facilitates the UK to become a worldwide center for biotech and pharma," a minister remarked.
Detailed NHS Changes
The pact entails several key changes from the United Kingdom:
- Price Threshold Increase: The UK will lift the cost ceiling at which it considers new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a aim to increase overall NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The sum manufacturers must refund to the NHS to control costs will be capped at fifteen percent. Previously, rebates were more than 20%.
Industry Background
This agreement takes place against a long-running row between the drug companies and the British authorities over medicine costs and regulatory access.
The disagreement were exacerbated by claims that US customers were paying significantly more for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or abandoned, while major expansions have been directed toward projects in the United States.
One official stated that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had decreased as a share of its total funding over the last ten years.
